Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Ganglioglioma
100%
Bevacizumab
100%
Temozolomide
100%
U87
100%
Neoplasm
41%
Extracellular Fluid
33%
Area under the Curve
25%
Glioblastoma
16%
Oral
16%
Contralateral
8%
Cancer Treatment
8%
Xenograft
8%
Combination Therapy
8%
Pharmacokinetics
8%
Antiangiogenic Therapy
8%
Cytotoxic Chemotherapy
8%
Liquid Chromatography-Mass Spectrometry
8%
Intracranial Tumor
8%
Keyphrases
Temozolomide
100%
U87 Glioma Cells
100%
Bevacizumab
100%
Tumor
33%
Extracellular Fluid
33%
Glioma
16%
Athymic Rat
16%
Combination Therapy
8%
Normal Brain
8%
Anticancer Therapy
8%
Glioblastoma
8%
Tumor-normal
8%
Glioma Model
8%
Pharmacokinetics
8%
Cytotoxic Therapy
8%
Xenograft Model
8%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
8%
Brain Concentration
8%
Tumor Brain
8%
Microdialysis
8%
Fluid Collection
8%
Area under the Concentration-time Curve
8%
Microdialysis Probe
8%
Anti-angiogenesis
8%
Intracranial Glioma
8%
Glioblastoma Xenografts
8%
Angiogenesis Therapy
8%
Mean Area
8%
Fluid Samples
8%
Tumor-bearing
8%
Non-tumor
8%
Pharmacology, Toxicology and Pharmaceutical Science
Bevacizumab
100%
Temozolomide
100%
Glioma
100%
Neoplasm
41%
Glioblastoma
16%
Microdialysis
16%
Nude Rat
16%
Malignant Neoplasm
8%
Combination Therapy
8%
Antiangiogenic Therapy
8%
Cytotoxic Chemotherapy
8%
Intracranial Tumor
8%
Pharmacokinetics
8%
Neuroscience
Bevacizumab
100%
Temozolomide
100%
Glioma
100%
Microdialysis
16%
Angiogenesis
8%
Liquid Chromatography-Mass Spectrometry
8%
Intracranial Tumor
8%
Pharmacokinetic
8%